Open AccessOrexin receptors in GtoPdb v.2021.3
Author(s) -
Paul J. Coleman,
Luı́s de Lecea,
Anthony L. Gotter,
Jim J. Hagan,
Daniel Hoyer,
Thomas S. Kilduff,
Jyrki P. Kukkonen,
Rod A. Porter,
John J. Renger,
Jerome M. Siegel,
Gregor Sutcliffe,
Neil Upton,
Christopher J. Winrow
Publication year - 2021
Publication title -
iuphar/bps guide to pharmacology cite
Language(s) - English
Resource type - Journals
ISSN - 2633-1020
DOI - 10.2218/gtopdb/f51/2021.3
Subject(s) - orexin , orexin a , receptor , orexin receptor , endogeny , chemistry , peptide , medicine , neuropeptide , biochemistry
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [42]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [109]. Currently the only orexin receptor ligands in clinical use are suvorexant and lemborexant, which are used as hypnotics. Orexin receptor crystal structures have been solved [134, 133, 54, 117, 46].